---
title: "BUZZ-Esperion falls after quarterly results miss estimates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278577175.md"
datetime: "2026-03-10T14:42:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278577175.md)
  - [en](https://longbridge.com/en/news/278577175.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278577175.md)
---

# BUZZ-Esperion falls after quarterly results miss estimates

Shares of drug developer Esperion Therapeutics (ESPR.O) fall 4.61% to $2.90 Co posts Q4 adjusted profit of 22 cents per share, compared to analysts’ estimate of 24 cents per share, according to data compiled by LSEG

Posts Q4 revenue of $168.4 million, missing analysts’ estimate of $174.5 million

ESPR shares down 22% YTD after having risen over 68% in 2025

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)

## Related News & Research

- [Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference](https://longbridge.com/en/news/282600951.md)
- [Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio](https://longbridge.com/en/news/281578871.md)
- [Esperion Insiders Quietly Cash Out as Top Executives Trim Their Stakes](https://longbridge.com/en/news/279718023.md)
- [EU sees 2025 pharma export uptick amid competitiveness concerns](https://longbridge.com/en/news/282719348.md)
- [Key facts: Esperion Sells Royalties to Athyrium; Modifies Credit Deal](https://longbridge.com/en/news/281659956.md)